Literature DB >> 17475427

Expression of PTEN protein in patients with laryngeal squamous cell carcinoma.

Kenan Guney1, Gulay Ozbilim, Alper Tunga Derin, Safiye Cetin.   

Abstract

OBJECTIVE: PTEN (phosphatase and tensin homologue deleted on chromosome 10), also referred to as MMAC1 (mutated in multiple advanced cancers) gene was recently identified as a putative tumor suppressor in a variety of malignant tumors. PTEN expression has been investigated in some squamous cell carcinomas (SCC) of head and neck. However, there is only little knowledge about laryngeal malignancies. Therefore, we examined PTEN product protein immunohistochemically in 30 consecutive laryngeal specimens from patients with laryngeal SCC and compared the results according to the clinicopathologic characteristics of the patients.
METHOD: Surgical resection specimens of patients with laryngeal SCC were stained for PTEN protein using a primary rabbit polyclonal anti-PTEN antibody. Standard avidin-biotin immunohistochemical analysis was used to process the sections. The extent and intensity of PTEN staining in the specimens were compared according to the age and sex of the patients and localization, differentiation, size and stage of the tumor.
RESULTS: Out of 30 tumoral specimens (23 glottic and 7 supraglottic) 22 showed decreased PTEN staining intensity compared to the adjacent normal tissue. The extent of cytoplasmic PTEN staining was significantly less in supraglottic tumors (p < 0.05). When characteristics of the patients were analyzed according to the extent of cytoplasmic PTEN staining no difference was observed according to age, sex, measure, differentiation, T or N status.
CONCLUSION: A significant decrease in the extent of PTEN staining was observed in supraglottic SCC. It could be worthwhile to test if PTEN expression is diminished in patients with more aggressive laryngeal tumors, with special attention to tumor localization in larger series.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17475427     DOI: 10.1016/j.anl.2007.03.014

Source DB:  PubMed          Journal:  Auris Nasus Larynx        ISSN: 0385-8146            Impact factor:   1.863


  6 in total

1.  Molecular and immunologic analysis of laryngeal squamous cell carcinoma in smokers and non-smokers.

Authors:  Ian-James Malm; Lisa M Rooper; Justin A Bishop; Selmin Karatayli Ozgursoy; Alexander T Hillel; Lee M Akst; Simon R Best
Journal:  Am J Otolaryngol       Date:  2018-11-22       Impact factor: 1.808

2.  The phosphatase and tensin homologue deleted on chromosome 10 mediates radiosensitivity in head and neck cancer.

Authors:  W J Pattje; E Schuuring; M F Mastik; L Slagter-Menkema; M L Schrijvers; S Alessi; B F A M van der Laan; J L N Roodenburg; J A Langendijk; J E van der Wal
Journal:  Br J Cancer       Date:  2010-05-25       Impact factor: 7.640

3.  Poor prognostic clinicopathologic features correlate with VEGF expression but not with PTEN expression in squamous cell carcinoma of the larynx.

Authors:  Yurdanur Sullu; Seda Gun; Sinan Atmaca; Filiz Karagoz; Bedri Kandemir
Journal:  Diagn Pathol       Date:  2010-06-14       Impact factor: 2.644

4.  PTEN Is Associated With Worse Local Control in Early Stage Supraglottic Laryngeal Cancer Treated With Radiotherapy.

Authors:  Leonie Bruine de Bruin; Jan E Wachters; Michiel L Schrijvers; Lorian Slagter-Menkema; Mirjam F Mastik; Johannes A Langendijk; Jacqueline E van der Wal; Ed Schuuring; Bernard F A M van der Laan
Journal:  Laryngoscope Investig Otolaryngol       Date:  2019-06-12

5.  Tbx3 represses PTEN and is over-expressed in head and neck squamous cell carcinoma.

Authors:  Durmus Burgucu; Kenan Guney; Duygu Sahinturk; Irem Hicran Ozbudak; Deniz Ozel; Gulay Ozbilim; Ugur Yavuzer
Journal:  BMC Cancer       Date:  2012-10-19       Impact factor: 4.430

6.  Tumorigenesis role and clinical significance of DJ-1, a negative regulator of PTEN, in supraglottic squamous cell carcinoma.

Authors:  Xiao-Lin Zhu; Zhang-Feng Wang; Wen-Bin Lei; Hui-Wen Zhuang; Wei-Jian Hou; Yi-Hui Wen; Wei-Ping Wen
Journal:  J Exp Clin Cancer Res       Date:  2012-11-14
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.